tislelizumab + bevacizumab + paclitaxel + cisplatin + carboplatin

This is a combination of five anti-cancer drugs: tislelizumab (an immune checkpoint inhibitor), bevacizumab (an angiogenesis inhibitor), paclitaxel (a chemotherapy drug), cisplatin (a platinum-based chemotherapy drug), and carboplatin (a platinum-based chemotherapy drug). Based on the provided search results, this exact five-drug combination is not specifically mentioned or described as a standard treatment regimen. The individual components and various subsets of these drugs are used in different combinations for treating conditions like advanced cervical cancer and other cancers, but the specific combination of all five together is not found in the search results.